Hansa Medical has appointed Sam Agus as it’s new chief medical officer, a role that will see him focus on building an effective company strategy around the global market for the launch of IdeS – a project based on kidney transplants in sensitised patients.
Agus has previously held various leading positions at several pharmaceutical companies including Shire, Solvay Pharmaceuticals, Abbott Laboratories and most recently at H.Lundbeck A/S as it’s chief specialist, medical affairs neurology.
With experience in medical strategy, multidisciplinary team leadership, medical marketing and clinical trial design, Agus’s therapy area expertise includes neurology, psychiatry, gastroenterology, women’s health and rare diseases.
Göran Arvidson, president and CEO of Hansa Medical, said: “We are very pleased to have Sam joining our team in this truly exciting phase for Hansa Medical.
“His experience from building and leading strong teams will be a central part in our next phase towards commercialisation of IdeS.”
Sam Agus succeeds Steven Glazer who will continue to provide strategic advice to Swedish biopharmaceutical firm Hansa.